Key result
Readministration of eptifibatide during percutaneous coronary intervention was associated with acute severe thrombocytopenia in a single case report.
Why the study?
Does readministration of eptifibatide cause acute severe thrombocytopenia in patients undergoing percutaneous coronary intervention?
Case Report (n=1)
Does readministration of eptifibatide cause acute severe thrombocytopenia in patients undergoing percutaneous coronary intervention?
Readministration of eptifibatide during PCI can cause acute severe thrombocytopenia, highlighting the need for platelet count monitoring post-administration.
Alerts clinicians to monitor platelets on eptifibatide reexposure; leaves open causality and incidence.
Thrombocytopenia following eptifibatide therapy is a rare event, and acute severe thrombocytopenia following readministration has not been reported. We describe a case of acute severe thrombocytopenia following reexposure to eptifibatide during percutaneous coronary intervention. We continue to monitor platelet counts at 2-4 hr and 16-24 hr following administration of any glycoprotein IIb/IIIa inhibitor. Cathet Cardiovasc Intervent 2001;54:63-67.
No takes yet. Share an insight, caveat, or question.
Paradiso‐Hardy et al. (2001) conducted a case report in Acute severe thrombocytopenia (n=1). Eptifibatide readministration was evaluated on Acute severe thrombocytopenia. Readministration of eptifibatide during percutaneous coronary intervention was associated with acute severe thrombocytopenia in a single case report.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: